Evidence map›Paper›PMID 40628853›Full record

ArticleScientific reports2025

Efficacy of measuring lysophosphatidylcholine levels in human cerebrospinal fluid to differentiate myelopathy from cauda equina syndrome.

Takuya Takahashi, Takashi Hirai, Masahiko Sumitani, Takao Mochizuki, Toru Akiyama, Atsushi Kimura, Kentaro Hayakawa, Eiji Takasawa, Hirotaka Chikuda, Toshitaka Yoshii and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Takuya TakahashiDepartment of Orthopedics, Institute of Science Tokyo, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan.
Takashi HiraiDepartment of Orthopedics, Institute of Science Tokyo, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan. hirai.orth@tmd.ac.jp.
Masahiko SumitaniDepartment of Pain and Palliative Medicine, The University of Tokyo Hospital, Tokyo, Japan.
Takao MochizukiDepartment of Orthopaedic Surgery, Saitama Medical Center, Jichi Medical University, Saitama, Japan.
Toru AkiyamaDepartment of Orthopaedic Surgery, Saitama Medical Center, Jichi Medical University, Saitama, Japan.
Atsushi KimuraDepartment of Orthopaedic Surgery, Jichi Medical University, Shimotsuke, Japan.
Kentaro HayakawaDepartment of Orthopaedics and Spine Surgery, Tokyo Metropolitan Institute for Geriatrics and Gerontology, Tokyo, Japan.
Eiji TakasawaDepartment of Orthopaedic Surgery, Gunma University, Maebashi, Japan.
Hirotaka ChikudaDepartment of Orthopaedic Surgery, Gunma University, Maebashi, Japan.
Toshitaka YoshiiDepartment of Orthopedics, Institute of Science Tokyo, 1-5-45 Yushima, Bunkyo-ku, Tokyo, 113-8510, Japan.
Makoto KuranoDepartment of Clinical Laboratory Medicine, The University of Tokyo Hospital, Tokyo, Japan.

Funding

esearch Project on the Elucidation of Chronic Pain 22ek0610028h0001Japan Agency for Medical Research and Development 19 lm0203084h001
6 · The paper itself

Abstract

Spinal stenosis frequently involves multiple regions, particularly the cervical and lumbar spine. Therefore, it is essential to identify biomarkers that can distinguish between central and peripheral neuropathy. Lysophosphatidylcholine (LPC), a biomarker involved in neuropathic pain, has been proposed as a potential diagnostic biomarker for distinguishing these conditions. This study aimed to evaluate the diagnostic utility of LPC levels in the cerebrospinal fluid (CSF) for differentiating peripheral neuropathy from central neuropathy. This study included 198 patients: 77 with cauda equina syndrome (CES), 34 with myelopathy, and 87 controls. CSF samples were collected by lumbar puncture. Using liquid chromatography-tandem mass spectrometry, six LPC species, including (16:0), (18:0), (18:1), (18:2), (20:4), and (22:6), were measured in the CSF. These LPC levels were compared among the groups, and the cutoff levels that could efficiently discriminate between the groups with high accuracy were determined. All levels of LPC species were significantly higher in the CES and myelopathy groups than in the controls, with CES showing the highest levels. LPC (18:1) and LPC (22:6) demonstrated high diagnostic accuracy in distinguishing CES from myelopathy. LPC (18:1), LPC (18:2), LPC (20:4), and LPC (22:6) demonstrated high diagnostic accuracy in distinguishing myelopathy from controls. The LPC species levels in CSF offer a reliable biomarker for differentiating CES from myelopathy. Measuring LPC species can enhance diagnostic accuracy, enabling precise treatment strategies.

Indexed as

Cauda Equina SyndromeLysophosphatidylcholinesSpinal Cord DiseasesAdultAgedBiomarkersCase-Control StudiesChromatography, LiquidDiagnosis, DifferentialFemaleHumansMaleMiddle AgedTandem Mass SpectrometryBiomarkersLysophosphatidylcholinesCauda equina syndromeCerebrospinal fluidLysophosphatidylcholineMyelopathy

Identifiers

PMID40628853
PMCPMC12238560

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.